Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802048 | 0.96 | CTSD (0.38) | MEN1KMT2ACTSDTGFBR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8430763 | 0.94 | MEN1 (0.37) | MEN1KMT2ACTSDTGFBR1ALDH1A1 | |
| SCHEMBL23641442 | 0.84 | TDP1 (0.37) | TGFBR1TDP1 | |
| SCHEMBL366720 | 0.82 | EGLN1 (0.47) | MEN1KMT2ATGFBR1ALDH1A1TDP1 | |
| SCHEMBL11139095 | 0.82 | EGLN1 (0.47) | MEN1KMT2ATGFBR1ALDH1A1TDP1 | |
| SCHEMBL8373315 | 0.80 | MCL1 (0.42) | MEN1KMT2ATGFBR1 | |
| SCHEMBL8379994 | 0.79 | MCL1 (0.39) | KMT2ATGFBR1ALDH1A1 | |
| SCHEMBL4893549 | 0.78 | TGFBR1 (0.35) | TGFBR1ALDH1A1KDM4E | |
| SCHEMBL8376801 | 0.77 | TGFBR1 (0.35) | TGFBR1ALDH1A1TDP1KDM4E | |
| SCHEMBL25968074 | 0.77 | TGFBR1 (0.35) | TGFBR1ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001905-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20220008543-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| US-20210214389-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA, LLC | 2021-07-15 | — | — | US | disclosed |
| US-20210214389-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA, LLC | 2021-07-15 | — | — | US | disclosed |
| EP-3843749-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | Osteoanalgesia, LLC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3843749-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | Osteoanalgesia, LLC (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020047231-A9 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020047231-A9 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020047231-A9 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020047231-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2020-03-05 | — | — | WO | disclosed |
| US-10172962-B2 | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-01-08 | — | — | US | disclosed |
| US-10092662-B2 | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180207296-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-07-26 | — | — | US | disclosed |
| EP-3269394-A1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | University of Utah Research Foundation (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-1737428-B1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | UNIV UTAH RES FOUND (US) | 2017-08-30 | — | — | EP | disclosed |
| CN-103936945-A | Novel efficient anti-tumor targeting drug carrier and preparation method thereof | CHINESE ACAD INST CHEMISTRY | 2014-07-23 | — | — | CN | disclosed |
| US-20090311182-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| US-20080159959-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1737428-A1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | University of Utah Research Foundation (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005097073-A1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008543-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | PLG, PYGL, PPIG | MEN1 425/4885KMT2A 3466/4885CTSD 2463/4885 |
| US-20090311182-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | MMP1, MSR1, CD68 | MEN1 3452/4885KMT2A 4274/4885CTSD 2400/4885 |
| US-20210214389-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | NR3C1, GCG, NR3C2 | MEN1 482/4885KMT2A 2522/4885CTSD 4172/4885 |
| US-20260001905-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | NR3C1, HLA-DRB1, NR3C2 | MEN1 2314/4885KMT2A 3589/4885CTSD 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.